بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

generics [uk] limited - amisulpridum - tabletki - 100 mg

بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

krka, d.d., novo mesto - dexamethasonum - tabletki - 0,5 mg

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - nowotwory piersi - Środki przeciwnowotworowe - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

krka, d.d., novo mesto - dexamethasoni natrii phosphas - roztwór do wstrzykiwań / do infuzji - 4 mg/ml

بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

krka, d.d., novo mesto - dexamethasoni natrii phosphas - roztwór do wstrzykiwań / do infuzji - 8 mg/2ml

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesylate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - Środki przeciwnowotworowe - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacjenci, którzy mają niskie lub bardzo niskie ryzyko nawrotu, nie powinni otrzymywać leczenie uzupełniające. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. za wyjątkiem zdiagnozowanych fazie przewlekłej cml, nie ma kontrolowanych badań, które wykazują efekt kliniczny lub zwiększa przeżywalność przy tych chorobach.

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizm aminokwasowy, wrodzone błędy - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

substipharm - chlorowodorek raloksyfenu - osteoporoza, postmenopauzalna - hormony płciowe i modulatory układu rozrodczego, - evista jest wskazany w leczeniu i zapobieganiu osteoporozie u kobiet po menopauzie. wykazano istotne zmniejszenie częstości występowania złamań kręgów, ale nie złamań biodra. when determining the choice of evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.